Patents by Inventor Mark Edmund Petersen

Mark Edmund Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE
    Publication number: 20240424125
    Abstract: Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FR?) (an anti-FR? antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.
    Type: Application
    Filed: May 29, 2024
    Publication date: December 26, 2024
    Inventors: James R. RICH, Stuart Daniel BARNSCHER, Mark Edmund PETERSEN, Raffaele COLOMBO, Michael G. BRANT, Manuel Michel Auguste LASALLE, Rupert H. DAVIES, Dunja UROSEV, Sukhbir Singh KANG, Peter Wing Yiu CHAN, Samir DAS, Andrea HERNANDEZ ROJAS, Robert William GENE, Ada G. H. YOUNG, Samuel Oliver LAWN, Danny CHUI, Duncan BROWMAN, Brandon CLAVETTE
  • BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE
    Publication number: 20240376154
    Abstract: Bis-intercalating peptide compounds having Formula I, which are capable of binding DNA and exerting a cytotoxic effect on cells, such as microbial, viral or tumour cells, and conjugates comprising the compounds linked to a targeting moiety, such as an antibody. The compounds and conjugates may be used in the treatment of cancer or a microbial or viral infection, or as diagnostic agents or labelling agents.
    Type: Application
    Filed: April 25, 2024
    Publication date: November 14, 2024
    Inventors: Mark Edmund Petersen, Geoffrey C. Winters, Manuel Michael Auguste Lasalle, Micheal G. Brant, Vincent K.C. Fung
  • CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE
    Publication number: 20240269309
    Abstract: Camptothecin analogues of Formula (I) and conjugates comprising the camptothecin analogues are described. The camptothecin analogues and conjugates may be used as therapeutic agents, particularly in the treatment of cancer, an autoimmune disease or a viral infection.
    Type: Application
    Filed: May 27, 2022
    Publication date: August 15, 2024
    Inventors: Mark Edmund Petersen, Michael Brant, Raffaele Colombo, james R. Rich, Manuel Michel Auguste Lasalle, Stuart Barnscher, Samir Das